Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Veterinary Medicine Market Access; Czech Republic (market access & pricing reform); European Union (Pharmaceutical Package legislation); Finland (IP); Germany (pricing & health care reform); Italy (pricing & health care reform); Norway (IP & market access); Poland (market access); Slovakia (IP & market access); Sweden (pricing & health care reform); United Kingdon (pricing & health care reform); Anti-Counterfeiting Trade Agreement; Latin America Free Trade Agreements; (CONTINUED ON NEXT PAGE) Canada (Pharmaceutical Market Access and Drug Safety Act - S 242 & access restrictions & IP); Cuba (omnibus bill & sanctions); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & access restrictions); Tunisia (IP & access restrictions); Egypt (IP); Saudia Arabia (IP & access restrictions); Peru (FTA Implementation); Argentina (IP & access restrictions); Chili (IP); Turkey (IP & access restrictions); Russia (IP & WTO accession); Israel (IP); Columbia (IP); South Africa (access restrictions); Japan (pricing & regulatory reform); China (anti-counterfeiting & pricing reform); Taiwan (pricing reform & IP); Korea (pricing reform); Thailand (CL); Indonesia (investment decree); Philippines (pricing reform);
Source: Senate LDA
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Physician Pathology Services Continuity Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Veterinary Medicine Market Access; Czech Republic (market access & pricing reform); European Union (Pharmaceutical Package legislation); Finland (IP); Germany (pricing & health care reform); Italy (pricing & health care reform); Norway (IP & market access); Poland (market access); Slovakia (IP & market access); Sweden (pricing & health care reform); United Kingdon (pricing & health care reform); Anti-Counterfeiting Trade Agreement; Latin America Free Trade Agreements; (CONTINUED ON NEXT PAGE) Canada (Pharmaceutical Market Access and Drug Safety Act - S 242 & access restrictions & IP); Cuba (omnibus bill & sanctions); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & access restrictions); Tunisia (IP & access restrictions); Egypt (IP); Saudia Arabia (IP & access restrictions); Peru (FTA Implementation); Argentina (IP & access restrictions); Chili (IP); Turkey (IP & access restrictions); Russia (IP & WTO accession); Israel (IP); Columbia (IP); South Africa (access restrictions); Japan (pricing & regulatory reform); China (anti-counterfeiting & pricing reform); Taiwan (pricing reform & IP); Korea (pricing reform); Thailand (CL); Indonesia (investment decree); Philippines (pricing reform);
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Food and Drug Import Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Food and Drug Import Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Physician Payments Sunshine Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Physician Payments Sunshine Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Comparative Effectiveness Research Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Comparative Effectiveness Research Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on Biologics (HR 1956)
Social Security Card Fortification Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Prescription Drug User Fee Act (S 1082 & HR 2900)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
Medicare Prescription Drug Price Negotiation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Medicare Prescription Drug Price Negotiation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (S 250 & HR 4), SCHIP
Universal Health Care Choice and Access Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Universal Health Care Choice and Access Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Department of Homeland Security Appropriations Act, 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
Department of Homeland Security Appropriations Act, 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on Biologics (S 1695)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Fair Medicaid Drug Payment Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
Medicare Enhancements for Needed Drugs Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (S 250 & HR 4), SCHIP
Medicare Enhancements for Needed Drugs Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Intellectual Property Rights Enforcement Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
To establish an office to oversee research compliance and assurance within the Veterans Health Administration of the Department of Veterans Affairs.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Small Business Expensing Permanency Act of 2003
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
To ratify the authority of the Federal Trade Commission to establish a do-not-call registry.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
To require cigarette products to be placed under or behind the counter in retail sales.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Intellectual Property Patent Reform (S3818)
Issues Related to Tuberculosis Funding
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · fourth_quarter · Q4
EU Duties; Market Access (China, Germany, Czech Republic, Italy, Norway, Poland, United Kingdom, Indonesia); Intellectual Property (Finland, Norway, China, Philippines); Pricing Reform (Czech Republic, Japan, Korea, Thailand)
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · third_quarter · Q3
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · year_end · YY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Follow-on Biologics (HR 1956)
Direct to Consumer Advertising
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · mid_year · MM
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Medicare (S 250 & HR 4), SCHIP
Follow-on Biologics (S 1695)
Prescription Drug User Fee Act (S 1082 & HR 2900)
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · year_end · YY
Health Care Reform Pricing Issues Importation
Intellectual Property Patent Reform (S3818)
International Trade Issues -- Peru FTA, Poland Price Cut, Germany Jumbo Groups, Japan Pricing & Regulatory Reform, Korea FTA, Russia WTO
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2005 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2004 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2003 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Health Technology
Medicare implementation Non-interference MMA & Patient Assistance Programs Mental Health Access
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)